Genmab Proposes Significant Share Capital Reduction by Cancelling Treasury Shares

summarizeSummary

Genmab A/S announced its Annual General Meeting, featuring a proposal to cancel DKK 2.47 billion worth of treasury shares, a move that will significantly reduce share capital and enhance shareholder value.

check_boxKey Events · Corporate Governance and Compliance · GMAB

• Proposed Share Capital Reduction

  Genmab A/S proposes to reduce its share capital by cancelling 1,900,000 treasury shares, which were repurchased for DKK 2,473,734,807.58 (approximately $359 million USD). This action is expected to enhance shareholder value by reducing the total share count.

• Annual General Meeting Convened

  The company will hold its Annual General Meeting on Thursday, March 19, 2026, to address various corporate governance matters, including the adoption of the audited Annual Report 2025 and the re-election of board members and auditors.

• Profit Carried Forward

  The profit of USD 963 million for the accounting year 2025 is proposed to be carried forward by transfer to retained earnings, rather than distributed as a dividend.

auto_awesomeAnalysis · GMAB · Life Sciences

Genmab A/S has announced its Annual General Meeting, where a key proposal includes a substantial reduction in share capital. The company plans to cancel 1,900,000 treasury shares, which were repurchased for approximately DKK 2.47 billion (around $359 million USD). This action is a positive move for shareholders as it reduces the number of outstanding shares, thereby enhancing earnings per share and overall shareholder value. Other agenda items, such as the adoption of the 2025 Annual Report and the re-election of board members and auditors, are routine corporate governance matters following the comprehensive 20-F filing on February 17, 2026.